Overview

A Study Evaluating the Safety, Tolerability and Efficacy of Two Injections of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

Status:
Completed

Trial end date:
2021-08-18

Target enrollment:

Participant gender:

Summary

The primary purpose of this phase 2, placebo-controlled, double-blind, parallel group study is to provide an initial evaluation of two intra-articular (IA) injections of SM04690 (each at the dose of 0.07mg per 2mL injection) approximately six months apart into the target knee of moderately to severely symptomatic osteoarthritis (OA) subjects. Subjects who complete this 52-week long study will be eligible to enter the extension phase for an additional 52 weeks of treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Biosplice Therapeutics, Inc.
Samumed LLC

Treatments:

Lorecivivint